Cristina Gasparetto, MD, Duke Cancer Institute

CASSIOPEIA Trial of Dara-VTd in Transplant-Eligible Myeloma

August 3rd 2021

Joseph Mikhael, MD, reviews updated results presented at the 2021 ASCO annual meeting of the phase 3 CASSIOPEIA trial for NDMM, and Nina Shah, MD, comments on how the data may inform the addition of daratumumab to triplet therapy at relapse.

Using IMiD-Based Strategies for Relapsed Myeloma

August 3rd 2021

Multiple myeloma experts discuss the role of pomalidomide-containing regimens for the treatment of RRMM.

Approaching Treatment of Relapsed/Refractory Myeloma

July 27th 2021

Factors to consider when approaching therapy selection for patients with multiple myeloma disease progression.

Role of MRD Assessment in Myeloma

July 27th 2021

Cristina Gasparetto, MD, leads the discussion on whether MRD testing can influence treatment decisions for newly diagnosed multiple myeloma.

Improving Maintenance Therapy for Myeloma

July 20th 2021

Multiple myeloma experts share their thoughts on improving on currently available maintenance therapy, particularly for high-risk patients, and review their personal approaches to maintenance therapy for standard- and high-risk disease.

High-Risk Multiple Myeloma: Selecting Initial Therapy

July 20th 2021

Sagar Lonial, MD, FACP, leads the discussion on selecting the optimal proteasome inhibitor, bortezomib or carfilzomib, for patients with high-risk multiple myeloma.

Standard Induction for Newly Diagnosed Symptomatic Myeloma

July 13th 2021

Experts in multiple myeloma comment on standard induction therapy for patients with newly diagnosed symptomatic myeloma and consider recommended triplet regimens.

Overview of Newly Diagnosed Multiple Myeloma

July 13th 2021

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss the diagnostic work-up for a patient with newly diagnosed multiple myeloma and the impact of age and frailty scores on transplant eligibility.

Rapid Readouts: Initial Results of the Phase III BOSTON Study

June 29th 2020

Dr. Gasparetto on Key Trials in Relapsed/Refractory Multiple Myeloma

August 2nd 2019

Cristina Gasparetto, MD, an associate professor of medicine, Duke University Medical Center, and director, Multiple Myeloma Program at Duke Cancer Institute, discusses key trials in relapsed/refractory multiple myeloma.

Dr. Gasparetto on Safety Concerns With Venetoclax in Multiple Myeloma

July 17th 2019

Cristina Gasparetto, MD, an associate professor of medicine and director, Multiple Myeloma Program at Duke Cancer Institute, discusses safety concerns with venetoclax (Venclexta) in multiple myeloma.

Dr. Gasparetto on Therapies for Patients With Penta-Refractory Myeloma

June 5th 2019

Cristina Gasparetto, MD, an associate professor of medicine and director, Multiple Myeloma Program at Duke Cancer Institute, discusses therapies for patients with penta-refractory multiple myeloma.

Dr. Gasparetto on Efficacy of Selinexor Combination in Multiple Myeloma

February 1st 2018

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discuss the efficacy of selinexor in combination with dexamethasone for the treatment of patients with multiple myeloma.

Dr. Gasparetto on Next Steps With Selinexor and Daratumumab in Multiple Myeloma

January 8th 2018

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses the next steps with selinexor and daratumumab (Darzalex) in multiple myeloma.

Dr. Gasparetto on Selinexor and Daratumumab Combination in Multiple Myeloma

December 19th 2017

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses a phase Ib study of the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma.

Dr. Gasparetto on Results for Selinexor and Daratumumab in Relapsed/Refractory Multiple Myeloma

December 11th 2017

Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting. Selinexor is an interesting new drug that inhibits Exportin 1 (XPO1), which reactivates some of the tumor suppressor proteins. In the phase 1b portion of the study, investigators aimed to identify the optimal dose of selinexor in combination with daratumumab. Gasparetto says the study included a small number of patients, but demonstrated very encouraging data.